- Product Detail
- Product Tags
- Buyer Reviews
Our enterprise insists all along the standard policy of "product high-quality is base of business survival; client satisfaction could be the staring point and ending of an business; persistent improvement is eternal pursuit of staff" as well as consistent purpose of "reputation first, client first" for Imatinib Mesilate API IMatinib-D4,Imatinib Base Gleevec Pills,Imatinib Mesilate Intermediate. Welcome to build the very well and extensive standing business enterprise interactions with our organization to make a wonderful long run together. customers' pleasure is our eternal pursuit!
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications).Product Name: Imatinib Mesilate
CAS NO: 220127-57-1
Standard: Enterprise Standard
Molecular Formula: C30H35N7O4S
Molecular Weight : 589.71
Description: White crystal or crystalline powder
Chemical names, synonyms:
4-[(4-methyl-1-piperazinyl)methyl]-n-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide monomethanesulfonate, STI-571, IMATINIB BASE(IMA-3), Imatinib (STI-571) Mesylate
Minimum purity: 99%
White to off-white Crystalline Powder
Identification By IR
IR spectrum of the sample should concordant to the standard spectrum.
Soluble in Water
NMT 0.5% w/w
Single Max. Imp : NMT 0.1 %
Total Max Imp : NMT 1.0 %
Assay (By HPLC)
NMT 98.0% And NLT 102 %
Imatinib Mesylate is a targeted therapy. Imatinib Mesylate is classified as a signal transduction inhibitor - protein-tyrosine kinase inhibitor.
A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.
Imatinib mesylate (also called Gleevec) is a small-molecule inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukemia.
As an inhibitor of PDGFR, imatinib mesylate appears to have utility in the treatment of a variety of dermatological diseases. Imatinib has been reported to be an effective treatment for FIP1L1-PDGFRalpha+ mast cell disease, hypereosinophilic syndrome, and dermatofibrosarcoma protuberans.
We stay with our company spirit of "Quality, Performance, Innovation and Integrity". We goal to create more value for our clients with our abundant resources, advanced machinery, experienced workers and superb solutions for 20127-57-1 Mesilate cas 152459-95-5. The product will supply to all over the world, such as: Belarus,Yugoslavia,San Marino. we are now looking forward to even greater cooperation with overseas customers based on mutual benefits. We will work wholeheartedly to improve our products and services. We also promise to work jointly with business partners to elevate our cooperation to a higher level and share success together. Warmly welcome you to visit our factory sincerely.
Email To This Supplier